{'fraction_non_alphanumeric': 0.023255813953488372, 'fraction_numerical': 0.0014534883720930232, 'mean_word_length': 5.207207207207207, 'pattern_counts': {'":': 0, '<': 0, '<?xml version=': 0, '>': 0, 'https://': 0, 'lorem ipsum': 0, 'www.': 0, 'xml': 0}, 'pii_count': 0, 'substrings_counts': 0, 'word_list_counts': {'cursed_substrings.json': 1, 'profanity_word_list.json': 0, 'sexual_word_list.json': 0, 'zh_pornsignals.json': 0}}
Adjuvant chemotherapy in new stage II pN0 non-small cell lung cancer: a new issue for a case-by-case decision making process.

Immunogenicity was not assessed. None of the patients developed influenza. In conclusion, we did not observe any relevant toxicity in patients with NSCLC treated with concomitant influenza vaccination and erlotinib. Although influenza vaccines are not devoid of risk, these data could assure clinicians and patients that they are safe for this subset of patients. Gianluca Spitaleri, MD Angelo Delmonte, MD Francesca Toffalorio, MD Tommaso Martino De Pas, MD Division of New Drug Development and Clinical Pharmacology European Institute of Oncology Milan, Italy